Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
about
Long-acting beta2-agonists for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseNew clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analysesTiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions."Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-effectiveness model.Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in SwedenCost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach.A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.Socioeconomic gradients in tiotropium use among adults with COPD.Medication adherence issues in patients treated for COPD.Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPDCost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.Converting condition-specific measures into preference-based outcomes for use in economic evaluation.Utility estimation in chronic obstructive pulmonary disease: a preference for change?Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium.Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Health State Utility Value in Chronic Obstructive Pulmonary Disease (COPD); The Challenge of Heterogeneity: A Systematic Review and Meta-Analysis.Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy modelCost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.Análisis de coste-utilidad de indacaterol frente a tiotropio en el tratamiento de la EPOC en España
P2860
Q24197467-B8998229-5014-4EC8-A78D-9579EF8C70BEQ24197853-4367EA25-E41F-47B5-AF95-7A356456ABBCQ24200476-B7EB9E55-4FC2-44C9-9890-30DD5EFAD426Q30419928-DFDDFF2B-71BD-44F4-A2D8-ED376970C396Q33693222-7B3809A2-3F53-4B53-965C-927FBC493B82Q33693227-7843AD38-3682-4D41-B019-7271BA7CCE06Q33732066-88126F01-004E-450D-84DC-483EF1CAE4FDQ33766133-EF05038A-9CC6-4B90-B7C6-F3FF0D883C9EQ35964698-4B59DF0F-2564-4655-8A82-4D8EEA9435C4Q36490676-9D5E994B-4D6A-4A2A-811E-DA0C9013CA4AQ36579746-AB146BD8-AA38-4ECF-B68D-0B65A3067EA8Q36875110-6715BE9E-E0BA-4B83-AAF7-408F1DD170D0Q37070328-B41A0574-9EF8-421A-B3E9-E7BFB12BF7D4Q37070340-691848DA-BC98-4CAD-B58B-1ACD05969B3CQ37261891-4297E978-0AB7-4473-A13C-6A98F5684C34Q37283438-FD380923-DB8A-4D40-8BC5-BECA31452CE3Q37310689-0917A922-1393-429E-A4FD-EAA271BBD4F9Q37698624-C22CEC8F-AD2B-484B-869E-E6225B9C168FQ37730578-1A82E163-298C-4AB5-A4D2-D1526BB317E3Q37763123-C6742541-30C7-4CB4-8031-0848291AEC46Q37944316-18B2364A-4787-4850-98F0-22C349A596FCQ37973132-0D81471E-1265-40F5-A27C-DBAA2E510284Q37992679-CD0B649A-0928-4A81-B5A2-D94879DA073BQ38068886-DCD235A5-DFAF-40EB-91DC-CA5E7E6AFA61Q38344780-F849B189-3FF4-48C4-B58A-CA4CC07FDE76Q38570714-EDAD7975-1AC8-491B-A201-7861BAA27AC2Q38672186-4BFDA268-A73D-4076-8E51-48DE7B3987DAQ39609265-93A18975-4CAD-42D6-8FF9-1150364EEEC1Q42020515-74A8713D-90E8-4CFB-B9EE-D2644EA91C98Q47138380-0737732B-9AC9-4EB2-8192-84E3DDCA6C29Q47380594-11E75BE6-2565-44D2-992B-D72EF4D9B862Q51287554-9BD346F3-04C2-4067-A251-24F462539879Q58840799-A05AECAD-18AC-4AA2-8977-8BFEEAF2B69B
P2860
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Modelling the 5-year cost effe ...... ve pulmonary disease in Spain.
@ast
Modelling the 5-year cost effe ...... ve pulmonary disease in Spain.
@en
type
label
Modelling the 5-year cost effe ...... ve pulmonary disease in Spain.
@ast
Modelling the 5-year cost effe ...... ve pulmonary disease in Spain.
@en
prefLabel
Modelling the 5-year cost effe ...... ve pulmonary disease in Spain.
@ast
Modelling the 5-year cost effe ...... ve pulmonary disease in Spain.
@en
P2093
P2860
P1476
Modelling the 5-year cost effe ...... ve pulmonary disease in Spain.
@en
P2093
Brigitta U Monz
Jan B Oostenbrink
Maureen P M H Rutten-van Mölken
P2860
P2888
P304
P356
10.1007/S10198-007-0039-4
P577
2007-03-17T00:00:00Z